AZD0120

Cell therapy

Phase 3underway

Evidence outlook · registrational

Multiple Myeloma: registrational readout pending

No completed mid-stage readout is on record. Registrational readout expected around 2028-06-14.

Also in development:Multiple Sclerosis · Phase 1Rheumatoid Arthritis · Phase 1/2Systemic Lupus Erythematosus · Phase 1/2

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Multiple Myeloma
NCT07764978 · AstraZeneca
2026-06-26 – 2034-05-12 · Newly Diagnosed Multiple Myeloma
What this study did
Phase 1/2 (7)
Multiple Myeloma
NCT05850234 · AstraZeneca
2023-07-20 – 2029-01-25 · Relapsed/Refractory Multiple Myeloma
What this study did
NCT06235229 · Gracell Biotechnologies (Shanghai) Co., Ltd.
2023-12-26 – 2026-03-02 · Multiple Myeloma
What this study did
NCT04935580 · Shanghai Changzheng Hospital
2021-06-28 – 2023-07-01 · Multiple Myeloma
What this study did
Rheumatoid Arthritis
Systemic Lupus Erythematosus
Other / comorbidity
NCT07081646 · Alexion Pharmaceuticals, Inc.
2025-08-18 – 2031-02-14 · Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, Amyloidosis
What this study did
Phase 1 (19)
Multiple Myeloma
NCT05840107 · Shanghai Changzheng Hospital
2023-05-04 – 2025-09-30 · Multiple Myeloma
What this study did
NCT05412329 · Shanghai Changzheng Hospital
2022-06-13 – 2024-06-01 · Multiple Myeloma
What this study did
NCT04236011 · Shanghai Changzheng Hospital
2020-01-16 – 2022-12-31 · Multiple Myeloma
What this study did
NCT04617704 · Shanghai Changzheng Hospital
2021-12-01 – 2022-02-01 · Multiple Myeloma
What this study did
Multiple Sclerosis
NCT07303790 · Daishi Tian
2026-03-09 – 2028-12-10 · Multiple Sclerosis
What this study did
NCT07364487 · Huashan Hospital
2026-01-26 – 2026-03-25 · Multiple Sclerosis
What this study did
Rheumatoid Arthritis
NCT07315503 · Institute of Hematology & Blood Diseases Hospital, China
2027-12 – 2041-01-15 · Rheumatoid Arthritis
What this study did
Systemic Lupus Erythematosus
NCT05846347 · Zhejiang University
2023-05-15 – 2025-04-19 · CAR-T
What this study did
Other / comorbidity
NCT07790575 · Saurabh Dahiya
2026-09 – 2041-07 · Cytopenia
What this study did
NCT07350837 · Tongji Hospital
2026-01-28 – 2029-12-31 · Highly Sensitized Patients Awaiting Kidney Transplant
What this study did
NCT07086404 · Daishi Tian
2025-09-15 – 2029-09-15 · Idiopathic Inflammatory Myopathy (IIM)
What this study did
NCT07072884 · Qiong Fu
2025-08-18 – 2029-03-31 · Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)
What this study did
NCT07250269 · Gracell Biotechnologies (Shanghai) Co., Ltd.
2025-10-29 – 2028-11-24 · Relapsed/Refractory AL Amyloidosis
What this study did
NCT06419166 · Zhejiang University
2024-12-01 – 2027-10-01 · Refractory Generalized Myasthenia Gravis
What this study did
NCT06759948 · Chongbo Zhao
2025-02-15 – 2027-09-10 · Generalized Myasthenia Gravis (gMG)
What this study did
NCT07058298 · Daishi Tian
2025-07-15 – 2027-09-10 · Generalized Myasthenia Gravis (gMG)
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Systemic Lupus Erythematosus: Phase 1/2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
AZD0120: this drugPhase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
AnifrolumabApprovedMonoclonal antibodyType I interferon receptor subunit 1 (IFNAR1)Partial signal
NCT04931563: Difference in Proportion of Participants Who Are Responders Between Anifrolumab and Placebo (Week 52): Anifrolumab 300mg 84/138 vs Placebo 46/138
NCT02446899: Number of Participants Who Achieved the British Isles Lupus Assessment Group Based Composite Lupus Assessment (BICLA) Response at Week 52 (Baseline; Week 52): Anifrolumab 300 mg 86/180 (47.8%) vs Placebo 57/182 (31.3%)
Belimumab (GSK1550188) (Benlysta)ApprovedMonoclonal antibodyBAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS)Weak signal
NCT00410384: SRI response at Week 52: 43.2% with belimumab 10 mg/kg vs 33.5% with placebo (p=0.0167); 40.6% with belimumab 1 mg/kg vs 33.5% with placebo (p=0.0889).
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Deucravacitinib (Sotyktu)Phase 3Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
LitifilimabPhase 3Monoclonal antibodyBDCA2 (CLEC4C), BDCA2 / CD303 (blood dendritic cell antigen 2)Reliable signal
NCT02847598: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 (Baseline to Week 24): Part A: BIIB059 50 mg -9 joints (Standard Deviation 5.7) | Part A: BIIB059 150 mg -13 joints | Part A: BIIB059 450 mg -14.5 joints (Standard Deviation 8.7) vs Part A: Placebo -12.7 joints (Standard Deviation 10.3)
Obinutuzumab Beta (Bejescin)Phase 3Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
Upadacitinib (Rinvoq)Phase 3Small moleculeJAK, JAK1not yet gradedNo reviewed efficacy summary in this indication
Voclosporin (Lupkynis)Phase 3Small moleculeCalcineurin, Cyclophilin A (leading to calcineurin inhibition)Reliable signalNo reviewed efficacy summary in this indication
AfimetoranPhase 2Small moleculeTLR7/8not yet gradedNo reviewed efficacy summary in this indication
BI 3000202Phase 2Small moleculecGAS (cyclic GMP-AMP synthase)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
EnvudeucitinibPhase 2Small moleculeTYK2Partial signal
NCT05966480: LUMUS trial (NCT05966480), primary endpoint BICLA response: envudeucitinib did not meet its primary endpoint in the overall trial population, but a prespecified IFNGS-high subgroup showed robust clinical responses on the same primary endpoint (BICLA). missed
FrexalimabPhase 2Monoclonal antibodyCD40 ligand (CD40L / CD154)not yet gradedNo reviewed efficacy summary in this indication
FT819Phase 2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
ICG318Phase 2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
InebilizumabPhase 2Monoclonal antibodyCD19not yet gradedNo reviewed efficacy summary in this indication
Nomelcitinib (D-2570)Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
ObexelimabPhase 2Monoclonal antibodyCD19 / FcγRIIbPartial signal
NCT02725515: Percentage of Patients Without Loss of Systemic Lupus Erythematosus Disease Activity Improvement on Day 225 (Day 225): XmAb5871 21/50 vs Placebo 12/42 missed
SanritatugPhase 2Monoclonal antibodyCD38Weak signalNo reviewed efficacy summary in this indication
TQH3906Phase 2Small moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
VENT-03Phase 2Small moleculecGAS (cyclic GMP-AMP synthase)not yet gradedNo reviewed efficacy summary in this indication
Zolacabtagene AutoleucelPhase 2Cell therapy—not yet gradedNo reviewed efficacy summary in this indication
Aritinercept
Phase 1/2(overall)
Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
Beijing Biotech Anti-CD19 CAR-TPhase 1/2Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
BudoprutugPhase 1/2Monoclonal antibodyCD19not yet gradedNo reviewed efficacy summary in this indication
DS-7011aPhase 1/2Monoclonal antibodyToll-like receptor 7 (TLR7) (inhibitor)Weak signal
NCT05638802: Treatment-emergent adverse events: 11/19 DS-7011a participants vs 4/6 placebo participants.
LisaftoclaxPhase 1/2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
SCTC21CPhase 1/2Biologic (subtype unspecified)CD38not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
ANX009Phase 1Antibody fragmentC1qnot yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
BCD-256Phase 1Monoclonal antibodyBDCA2 (CLEC4C)not yet gradedNo reviewed efficacy summary in this indication
BCMA-CD19 Compound CAR (cCAR) T CellsPhase 1Cell therapyBCMA / CD19Weak signal
NCT05474885: All patients (12/13) who received an initial dose of 3x10^6 cCAR cells/kg were negative for all autoantibodies, including those derived from long-lived plasma cells, 3 months post-cCAR. Therapy was well tolerated with mild cytokine-release syndrome (no CRS above grade 1), and mean SLE Disease Activity Index 2000 (SLEDAI-2K) fell from 9.9 at baseline to 2.3 at 3 months.
BZE2204Phase 1Cell therapyCD19, CD22, and BCMA (tri-antigen)not yet gradedNo reviewed efficacy summary in this indication
CevostamabPhase 1Multispecific antibodyFcRH5 (FcRL5) x CD3not yet gradedNo reviewed efficacy summary in this indication
CizutamigPhase 1Multispecific antibodyBCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
Divozilimab (Ivlizi)Phase 1Monoclonal antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
F01Phase 1Cell therapy—not yet gradedNo reviewed efficacy summary in this indication
GSK4527363Phase 1——not yet gradedNo reviewed efficacy summary in this indication
GSK5926371Phase 1Biologic (subtype unspecified)CD19 / CD20 (dual-antigen) with CD3 T-cell engagementnot yet gradedNo reviewed efficacy summary in this indication
HC022Phase 1——Weak signalNo reviewed efficacy summary in this indication
IC19 CAR-TPhase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
LBL-047Phase 1Protein / enzyme therapeuticBDCA2 (CLEC4C) / TACInot yet gradedNo reviewed efficacy summary in this indication
NIM-1324
Phase 1(overall)
Small moleculeLANCL2not yet gradedNo reviewed efficacy summary in this indication
OdronextamabPhase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
PIT565Phase 1Multispecific antibodyCD19 x CD2 x CD3not yet gradedNo reviewed efficacy summary in this indication
SAR448501Phase 1Multispecific antibodyCD20not yet gradedNo reviewed efficacy summary in this indication
SurovatamigPhase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
UTAA09Phase 1Cell therapyCD19Weak signalNo reviewed efficacy summary in this indication
UTAA91Phase 1Cell therapyCD19 (B cells) and PD-1+ pathogenic T cellsnot yet gradedNo reviewed efficacy summary in this indication
VonsetamigPhase 1—BCMA x CD3not yet gradedNo reviewed efficacy summary in this indication
ZM001Phase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
Zugocabtagene GeleucelPhase 1Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
FT522
—(overall)
Cell therapyCD19not yet gradedNo reviewed efficacy summary in this indication
GRI-0803
—(overall)
Small moleculeType 2 NKT cells (activator)not yet gradedNo reviewed efficacy summary in this indication
AB-101 (AlloNK)DiscontinuedCell therapyCell therapynot yet gradedNo reviewed efficacy summary in this indication
CadefrecitinibDiscontinuedSmall moleculeTYK2not yet gradedNo reviewed efficacy summary in this indication
GLPG3970DiscontinuedSmall moleculeSIK2/3not yet gradedNo reviewed efficacy summary in this indication
SolcitinibDiscontinuedSmall moleculeJAK1, JAK1not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 1 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(19 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow AZD0120 to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 1Highly Sensitized Patients Awaiting Kidney TransplantRecruiting
Est. primary completion 2026-12-31 · NCT07350837 · CT.gov ↗
What to watch
2027 (7)
January 2027 (1)
Phase 1Multiple SclerosisRecruiting
Est. primary completion 2027-01-20 · NCT07303790 · CT.gov ↗
What to watch
February 2027 (3)
Phase 1/2Systemic Lupus ErythematosusActive not recruiting
Est. primary completion 2027-02-01 · NCT06530849 · CT.gov ↗
What to watch
Phase 1Generalized Myasthenia Gravis (gMG)Not yet recruiting
Est. primary completion 2027-02-13 · NCT06759948 · CT.gov ↗
What to watch
Phase 1Generalized Myasthenia Gravis (gMG)Recruiting
Est. primary completion 2027-02-13 · NCT07058298 · CT.gov ↗
What to watch
March 2027 (1)
Phase 1Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM)Not yet recruiting
Est. primary completion 2027-03-31 · NCT07072884 · CT.gov ↗
What to watch
September 2027 (1)
Phase 1Idiopathic Inflammatory Myopathy (IIM)Recruiting
Est. primary completion 2027-09-15 · NCT07086404 · CT.gov ↗
What to watch
October 2027 (1)
Phase 1/2Multiple MyelomaRecruiting
Est. primary completion 2027-10-01 · NCT05850234 · CT.gov ↗
What to watch
2028 (7)
February 2028 (1)
Phase 1/2Rheumatoid ArthritisRecruiting
Est. primary completion 2028-02-22 · NCT07295847 · CT.gov ↗
What to watch
May 2028 (1)
Phase 1Multiple MyelomaRecruiting
Est. primary completion 2028-05-26 · NCT07073547 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-06-14 · NCT07391657 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1Systemic Lupus ErythematosusRecruiting
Est. primary completion 2028-08-10 · NCT05858684 · CT.gov ↗
What to watch
November 2028 (2)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2028-11-02 · NCT07735637 · CT.gov ↗
What to watch
Phase 1Relapsed/Refractory AL AmyloidosisRecruiting
Est. primary completion 2028-11-24 · NCT07250269 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1Multiple SclerosisRecruiting
Est. primary completion 2028-12-12 · NCT07224373 · CT.gov ↗
What to watch
2029 (3)
January 2029 (1)
Phase 3Multiple MyelomaRecruiting
Est. primary completion 2029-01-11 · NCT07764978 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1/2Systemic Lupus ErythematosusRecruiting
Est. primary completion 2029-05-01 · NCT06897930 · CT.gov ↗
What to watch
August 2029 (1)
Phase 1/2Relapsed AL Amyloidosis, Refractory AL Amyloidosis, Light Chain Amyloidosis, AmyloidosisRecruiting
Est. primary completion 2029-08-15 · NCT07081646 · CT.gov ↗
What to watch
2041 (1)
July 2041 (1)
Phase 1CytopeniaNot yet recruiting
Est. primary completion 2041-07 · NCT07790575 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

Q1 2026PresentationDURGA-1 Phase 1b/2 (NCT05850234) data at the 2026 Tandem Meetings: overall response rate 96%